Clinician's Roundtable

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Host: Jennifer Caudle, DO Guest: Sayantani Sindher, MD Recently, Omalizumab was studied in patients due to the avoidance of management and guidance when it comes to treating food allergies in children and adults. According to this doctor, approximately 45 percent of patients seen in his clinic have multi-food allergies that are not being met with current treatment options. So to explain his research, Dr. Jennifer Caudle is joined by Dr. Sayantani Sinder, Clinical Associate Professor of Medicine and Pediatric Allergy and Clinical Immunology Physician at Stanford Healthcare and Stanford Medicine Children’s Health.

Guest: Douglas Jones, MD A recent study was done to show the side effects of diphenhydramine for allergic reactions, and one of the main detriments was that it could impair the patient by making them tired or sleepy. Another finding was that it doesn’t work that quickly, so in turn, giving diphenhydramine in a severe allergic reaction could cause more harm than good. To learn more on what you should know before using diphenhydramine in allergic reaction situations and possible better solutions, tune in with Dr. Douglas Jones, Board-Certified Allergist and Immunologist with the Tanner Clinic in Layton, Utah.

Guest: Gates B. Colbert, MD A class of medications called SGLT2 inhibitors have been proven to make a major difference for patients with chronic kidney disease (CKD) with and without diabetes when added to angiotensin converting enzyme (ACE) and angiotensin receptor blockers (ARB) classes of medications. Several medications that have been well studied and approved by the FDA in the United States have shown progression of not only CKD but also cardiovascular events and overall mortality. To learn more about these medications, join Dr. Gates Colbert, Assistant Clinical Professor of Medicine at Texas A&M College of Medicine, and Nephrologist and Certified Hypertension Specialist at Kidney and Hypertension Associates of Dallas.

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Clinicians experiencing substance abuse disorder (SUD) may have some reluctance about utilizing a Physician Health Program; however, it’s important to know what your resources are in terms of formal treatment and to seek a psychiatrist with addiction specialization. Dive into part two of this discussion to learn more about the valuable resources and programs that can help physicians recover from SUD with Dr. Michael Greenberg and Dr. Chris Bundy, Executive Medical Director of the Washington Physicians Health Program and Clinical Assistant Professor of Psychiatry at the University of Washington School of Medicine.

Host: Ashley Baker, MSN, PMHNP Guest: Chi D. Chu, MD, MAS The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awareness, tune into this discussion with Psychiatric Nurse Practitioner Ashley Baker as she takes a deep dive with Dr. Chi D. Chu, Assistant Professor of Medicine in the Division of Nephrology at the University of California San Francisco and coauthor of the article published in the American Journal of Kidney Diseases, titled “CKD Awareness Among US Adults by Future Risk of Kidney Failure.

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Along with the general population, physicians are vulnerable to substance use disorder (SUD) with rates as high as 10 to 14 percent. And with demanding careers, stress and burnout can often exacerbate SUD. Tune into part one of this discussion with Dr. Michael Greenberg as he takes a deep dive into the prevalence of SUD and use characteristics among physicians with Dr. Chris Bundy, Executive Medical Director of the Washington Physicians Health Program and Clinical Assistant Professor of Psychiatry at the University of Washington School of Medicine. Read the original publication, titled "The Whole Physician: Physicians with Substance Use Disorder: Help is Available," which was published on Practical Neurology in November 2023.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Justin Reinert, PharmD Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by the rapid onset of widespread inflammation in the lungs, but inhaled epoprostenol can be used as a last-line treatment strategy for these patients. Learn more about this treatment option’s efficacy and safety with Dr. Charles Turck and Dr. Justin Reinert, Assistant Professor of Clinical Pharmacy at the University of Toledo.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Basil M. Kahwash, MD Patients with asthma could benefit greatly from exercising, and over time, it could lead to better asthma control. Dive into this episode to learn more about the findings from a recent study on exercise and asthma with Dr. Mary Katherine Cheeley and Dr. Basil Kahwash, Assistant Professor of Medicine on the Clinical Educator track in the Division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt University in Nashville, Tennessee.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ananta Paine, PhD The diagnosis of psoriatic arthritis has not been easy due to the lack of knowledge about an established biomarker. To learn more, join Dr. Charles Turck as he speaks with Dr. Ananta Piane, Principal Investigator and Research Assistant Professor at the University of Rochester Medical Center in Rochester, New York, to discuss his 500-patient cohort study to find out if there are underlying differences of psoriasis patients who did not convert to psoriatic arthritis with those who did.